MedTrace Logo

A Study in Schizophrenic Patients

NCT01125358 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2021-09-14

Study results available
· View outcomes & findings →

Summary

This study is designed to compare 3 doses of LY2140023 for the treatment of schizophrenia as assessed at endpoint (up to 7 weeks) using the Clinical Utility Index (CUI), a measure of efficacy, safety, and tolerability.

Conditions

Interventions

DRUG

LY2140023

Administered orally, twice daily for up to 7 weeks of treatment

DRUG

Placebo

Administered orally, twice daily for up to 7 weeks of treatment

Sponsors & Collaborators

  • Denovo Biopharma LLC

    lead INDUSTRY

Principal Investigators

  • Call 1-877-CTLILLY(1-877-285-4559) or 1-317-615-4459 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2012-09-30
Completion
2012-09-30

Countries

  • Japan
  • South Korea
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01125358 on ClinicalTrials.gov